Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.
Stephanie KullmannJulia HummelRobert WagnerCorinna DanneckerAndreas VosselerLouise FritscheRalf VeitKonstantinos KantartzisJürgen MachannAndreas L BirkenfeldNorbert StefanHans-Ulrich HäringAndreas PeterHubert PreisslAndreas FritscheMartin HeniPublished in: Diabetes care (2021)
Our results corroborate insulin resistance of the hypothalamus in humans with prediabetes. Treatment with empagliflozin for 8 weeks was able to restore hypothalamic insulin sensitivity, a favorable response that could contribute to the beneficial effects of SGLT2 inhibitors. Our findings position SGLT2 inhibition as the first pharmacological approach to reverse brain insulin resistance, with potential benefits for adiposity and whole-body metabolism.
Keyphrases
- insulin resistance
- placebo controlled
- double blind
- adipose tissue
- metabolic syndrome
- high fat diet
- polycystic ovary syndrome
- skeletal muscle
- type diabetes
- high fat diet induced
- clinical trial
- study protocol
- phase iii
- white matter
- randomized controlled trial
- phase ii study
- multiple sclerosis
- combination therapy
- risk assessment
- blood brain barrier
- rectal cancer
- human health
- subarachnoid hemorrhage
- open label
- locally advanced